Y. Zhu

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

B. Han, G. Jiang, H. Pan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study

C. Bai, Yi-long Wu, G. Jiang, 2013, Clinical and Translational Oncology.

Phase III KEYNOTE-590 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer.

M. Shah, P. Enzinger, Y. Zhu, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

1176P Neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in patients with potentially resectable NSCLC: An open-label, single-arm, phase II trial

Y. Zhu, J. Yang, X. Zhu, 2021, Annals of Oncology.

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

B. Han, G. Jiang, H. Pan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.